The World Health Organization has restricted the use of Ervebo in responding to a Bundibugyo outbreak. According to the organization, Ervebo should only be used against the Bundibugyo virus within a research protocol. This restriction is intended to generate evidence on the effectiveness of Ervebo, rather than using it for broader routine outbreak vaccination.

Further details on this restriction are available from the source. The decision indicates a cautious approach to using Ervebo in this context, highlighting the need for more evidence on its effectiveness.

The source provides more information on this development, which can be consulted for additional context.